Qui est qui dans la recherche sur la longévité
Un panorama des chercheurs, instituts et entreprises qui comptent dans le domaine de la longévité.
43 chercheurs · 7 disciplines · 11 instituts · 17 entreprises
Une sélection choisie, non exhaustive, de noms reconnus, classés par discipline et volontairement pas par notoriété ni par influence.
Pour chacun, nous indiquons franchement sa position dans le domaine : salarié / fondateur veut dire salarié, fondateur ou actionnaire d’une entreprise du domaine, conseil / brevet signale des intérêts de conseil ou de brevet, et aucun intérêt connu veut dire que nous n’avons rien trouvé dans les sources publiques et les déclarations d’intérêts ; ce n’est pas une garantie. Pour la recherche elle-même, parcours nos thèmes et ce qui marche.
Aging clocks & biomarkers
Developed the first multi-tissue epigenetic aging clock in 2013, now the standard for measuring biological age.
Developed the PhenoAge clock, which predicts not just age but also disease risk.
Cellular reprogramming
2012 Nobel Prize for iPS cells: proved that adult cells can be reset to a young state, the foundation of the entire reprogramming field.
Discovered epigenetic reprogramming in development and demonstrated substantial rejuvenation of human cells through partial reprogramming.
First to show that partial reprogramming can reverse hallmarks of aging in living mice.
Discovered the senescence gene p16 and connects senescence research to rejuvenation via reprogramming.
Studies the epigenetic information-loss theory of aging, and is at once the most visible and most criticized public voice on lifespan.
Senescence & senolytics
Co-founder of the senolytics field: coined the term and ran the first human studies on clearing senescent cells.
Conceived the senolytics concept with Kirkland and developed the biomarkers and models of senescent cells.
Uncovered the molecular control of cellular senescence, including senolysis via GLS1 inhibition.
Genetics of exceptional longevity
Identified human longevity genes through centenarians and initiated the metformin trial TAME.
Discovered that a single gene (daf-2) doubles the lifespan of worms, showing that aging is genetically controllable.
Founder of the Leiden Longevity Study into the genetics and biomarkers of healthy aging in families.
Founder of the New England Centenarian Study, the largest centenarian study, and an outspoken critic of the anti-aging industry.
Showed in centenarians that reduced IGF-1 activity is associated with exceptional longevity.
Nutrition, metabolism & known drugs
Put rapamycin on the map as a candidate aging drug and is co-founder of the Dog Aging Project.
Leading figure of the ITP, the most rigorous program testing which compounds actually extend the lifespan of mice.
Founder of the fasting-mimicking diet and of the research connecting nutrition to the pathways of aging.
Leading research on caloric restriction and fasting patterns in mice and rhesus monkeys.
Unravels the mTOR pathway and showed that low-protein diets and restriction of BCAA amino acids improve metabolic health.
Studies how sirtuins, NAD+ and ketone bodies drive the aging process and inflammation.
Discovered the TOR/mTOR protein, the switch controlling cell growth and aging and the target of rapamycin. 2024 Balzan Prize for the biological mechanisms of ageing.
Uncovered the role of spermidine in autophagy and cell protection, turning it into a fast-growing research field (spermidine as a fasting mimetic).
Fundamental & comparative biology
Lead author of The Hallmarks of Aging, the influential framework that defines the core processes of aging.
Discovered the role of mitochondrial membrane permeabilization in cell death and is a leader in autophagy research.
Pioneered showing that diet and signaling pathways slow aging, consistently from fruit fly to mouse.
Pioneer of comparative aging biology, using long-lived species to study why organisms age so differently.
Built the widely used open databases on aging (AnAge, GenAge, DrugAge) that supply the field with data.
Showed with the naked mole-rat that high-molecular-weight hyaluronan is the key to its cancer resistance and long life.
Mapped the evolution of tumor suppression toward lifespan and, with Gorbunova, identified the hyaluronan mechanism.
Leads China's hub in aging biology: aging clocks, stem cells and the Aging Biomarker Consortium.
Uncovered the central role of DNA damage in aging, including the discovery of the DREAM complex.
One of the world's foremost telomere researchers, who demonstrated telomerase gene therapy in mice.
Mapped the networks behind long life and age-related memory loss using the roundworm C. elegans.
Mapped the metabolic and hormonal control of lifespan, from worm to vertebrate (C. elegans and killifish).
Showed how telomere dysfunction drives stem-cell aging; former scientific director of the FLI.
Longevity medicine & prominent voices
Dutch physician-researcher bringing clinical longevity medicine into practice through large cohort studies and trials.
Uncovered the role of sirtuins and the mTOR pathway in aging; former CEO of the Buck Institute.
Instituts de référence
The world's first independent institute wholly dedicated to the biology of aging.
The US federal institute that leads and funds aging research.
European hub for the molecular and evolutionary mechanisms of aging.
The oldest and largest academic gerontology school in the world.
Chinese hub for aging and regeneration research.
Home of the Longevity Genes Project and the TAME trial.
Leading German university cluster on cellular stress responses in aging-associated diseases.
Germany's first biomedical aging institute (2004); stem-cell aging and molecular damage.
Where the TOR/mTOR protein was discovered, the foundation of the rapamycin story.
Startups innovantes
D'où vient une bonne partie des travaux les plus récents (et les plus survendus). Objet et stade indiqués de façon neutre.
Heavily funded company using cellular reprogramming to rejuvenate cells (~$3 billion in initial capital).
Alphabet/Google subsidiary researching the fundamental biology of aging.
Aims to extend healthy lifespan by ten years; funded by Sam Altman.
Resets aged cells to a younger gene-expression pattern; founded by Brian Armstrong.
Develops partial-reprogramming therapy; first human trial approved by the FDA (2026).
Develops senolytic drugs that clear aged cells, with a focus on eye diseases.
Develops gene therapies against aging; spun out of George Church's lab.
Drug development based on human aging data; now focused on obesity and metabolic disease.
Uses generative AI for drug discovery in aging and fibrosis.
Develops drugs that extend the healthy lifespan of dogs, with FDA recognition for senior dogs.
Physics-first AI platform that models the dynamics of aging to find drugs.
Develops mRNA drugs (ERA platform) that reverse the epigenetic age of cells.
Clinical-stage; oral small molecules that induce mitophagy to restore mitochondrial function (€116m raised).
Swiss platform (formerly Rejuveron) building therapies against hallmarks of aging: senescence, telomeres and stem cells.
Develops gene therapy based on a centenarian SIRT6 variant (GF-1002).
Spun out of EPFL; developed urolithin A (Mitopure) for mitochondrial health.
Develops spermidine supplements (spermidineLIFE) based on the research of Frank Madeo.
Liens d'intérêts vérifiés en août 2026 à partir de sources publiques et de déclarations d'intérêts ; les affiliations et les intérêts peuvent changer. Tu vois une erreur ou un nom qui manque ? Dis-le-nous.